Trial · NCT01476787
Adverse events1,516
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,516
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ANAEMIA | Blood and lymphatic system disorders | Rituximab-Lenalidomide | 25 | 507 | |
| other | ANAEMIA | Blood and lymphatic system disorders | Investigator Choice Rituximab-CHOP | 44 | 365 | |
| other | ANAEMIA | Blood and lymphatic system disorders | Investigator Choice Rituximab-CVP | 3 | 26 | |
| other | ANAEMIA | Blood and lymphatic system disorders | Investigator Choice Rituximab-Bendamustine | 8 | 112 | |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Rituximab-Lenalidomide | 22 | 507 | |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Investigator Choice Rituximab-CHOP | 47 | 365 | |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Investigator Choice Rituximab-CVP | 2 | 26 | |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Investigator Choice Rituximab-Bendamustine | 7 | 112 | |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | Rituximab-Lenalidomide | 7 | 507 | |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | Investigator Choice Rituximab-CHOP | 19 | 365 | |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | Investigator Choice Rituximab-CVP | 1 | 26 | |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | Investigator Choice Rituximab-Bendamustine | 1 | 112 | |
| other | NEUTROPENIA | Blood and lymphatic system disorders | Rituximab-Lenalidomide | 199 | 507 | |
| other | NEUTROPENIA | Blood and lymphatic system disorders | Investigator Choice Rituximab-CHOP | 172 | 365 | |
| other | NEUTROPENIA | Blood and lymphatic system disorders | Investigator Choice Rituximab-CVP | 7 | 26 | |
| other | NEUTROPENIA | Blood and lymphatic system disorders | Investigator Choice Rituximab-Bendamustine | 25 | 112 | |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | Rituximab-Lenalidomide | 17 | 507 | |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | Investigator Choice Rituximab-CHOP | 14 | 365 | |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | Investigator Choice Rituximab-CVP | 0 | 26 | |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | Investigator Choice Rituximab-Bendamustine | 11 | 112 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01476787/events